Apotex 2nd biosimilar under FDA review; seeks filgrastim OK
The FDA is reviewing a second biosimilar application from Canadian drug maker Apotex – this time a version of Amgen's Neupogen (filgrastim), which made about $1bn in sales last year.
The FDA is reviewing a second biosimilar application from Canadian drug maker Apotex – this time a version of Amgen's Neupogen (filgrastim), which made about $1bn in sales last year.